Merck Stock (NYSE:MRK)
In addition to breaking ground on a new factory in Singapore that would make inhalers, Merck (NYSE:MRK) said on October 5 that it had launched a new secondary packaging facility to support the manufacturing of vaccines and biologics, including immunotherapies. As a result, Merck stock surged in the market.
Merck’s (NYSE:MRK) investment, which will total up to $500 million over the next five years and begin in 2020, will include constructing the production facilities.
1997 marked the beginning of Merck’s (NYSE:MRK) manufacturing activities in Singapore. The facilities may be found inside an existing industrial cluster that encompasses 72 acres and is situated in Tuas, Singapore.
The semi-automated vial-packaging line will produce the Merck stock blockbuster cancer drug Keytruda (pembrolizumab), and the fully automated syringe-packaging lines will be used to produce the HPV vaccine Gardasil 9. The secondary packaging facility will have a total of four semi-automated packaging lines.
In the previous year, the location had initiated the sterile filling procedure for Keytruda. According to a news statement issued by the firm on October 5, the expansion has resulted in the addition of secondary packaging, cold storage, and a quality control laboratory.
Merck stock also said that the new inhaler medicine plant, scheduled to be completed in the year 2026, would develop inhalation devices for the next generation for the targeted administration of medications.
According to Merck (NYSE:MRK), the investment is anticipated to create more than 100 new positions during the next few years, raising the total number of workers working for Merck stock in Singapore to more than 1,800 in the next few years.
Singapore is becoming more appealing to pharmaceutical companies as a result of Sanofi’s plan to invest €400 million over five years for a vaccine production site and BioNTech’s announcement from the previous year that it would establish a regional headquarters for South East Asia in Singapore. Both of these plans were made public in April. Currently located in the Asian nation, GSK has vaccine production facilities.
Featured Image- Megapixl @ Michaelvi
Author Shariq Khan 
